Purchase this article with an account.
J. A. Clever, L. Akduman; Nepafenac Used for the Treatment of Chronic Pseudophakic Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4155.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We evaluated the efficacy of nepafenac in chronic pseudophakic cystoid macular edema (CME) unresponsive to other topical medications.
We reviewed the records of 9 consecutive patients (9 eyes) who were switched to nepafenac for chronic pseudophakic CME. Initial and final best corrected visual acuity (BCVA), initial and final central foveal thickness (CFT) via optical coherence tomography (OCT), and previous and concomitant medications were noted.
All patients but one received nepafenac alone. One patient used topical prednisolone along with nepafenac. Previous medications discontinued were topical ketorolac, flurbiprofen, and prednisolone. Mean BCVA improved from 20/96 (range: 20/40 to 20/200) to 20/78 (range: 20/25 to 20/200) in a mean follow-up time of 4 months. CFT improved by 22.4% (from 397µ to 308µ). Rechallenge with nepafenac in two patients who recurred resulted in resolution of edema in one month.
Nepafenac appears to be effective in chronic pseudophakic CME unresponsive to other to topical medications.
This PDF is available to Subscribers Only